中国人兽共患病学报2024，Vol.40Issue(3)：203-207,5.DOI:10.3969/j.issn.1002-2694.2024.00.042
2020-2022年湖南省鼠类钩端螺旋体病监测与菌株分型
Epidemiological surveillance and typing of Leptospira strains in rodents in Hunan Province during 2020-2022
摘要
Abstract
To investigate the epidemiology and conduct etiological characterization of pathogenic Leptospira,we trapped 461 rodents and soricidae belonging to seven species in four regions with leptospirosis cases in Hunan province during 2020-2022.The density of rodents was 2.52％,and the most prevalent rodent species in these four regions was Apodemus agrarius.A total of 56 pathogenic Leptospira isolates from Apodemus agrarius,Rattus flavipectus and Sorex araneus Linnaeus were successfully isolated;the isolation rate in rodents was 12.15％.Microscopic agglutination tests(MATs)with 15 Chinese stand-ard serogroup-specific rabbit antisera were conducted for serogroup identification.Multilocus sequence typing(MLST)based on seven loci(glmU,pntA,sucA,tpiA,pfkB,mreA and caiB)was performed for genotyping.Two serogroups were identified among the 56 Leptospira isolates.Icterohaemorrhagiae was the dominate serogroup,accounting for 94.64％.Three se-quence types(STs),ST1,ST128 and ST105,were identified through MLST analysis.ST1(57.14％)and ST128(37.50％)were the dominant STs in Hunan.Phylogenetic analysis using UPGMA in BioNumerics software version 5.1 identified three clades(clades 1-3)corresponding to three different STs a-mong the 56 pathogenic Leptospira isolates.The leptospiral diversity of STs differed across animal species and regions in Hunan.Icterohaemorrhagiae was the main serogroup;and ST1 and ST128 were the main STs in Hunan.The epidemiology of rodents and the detailed serological and molecular characteristics of strains circulating in this province may aid in developing strategies or guidelines for vaccine preparation and the control of leptospirosis in Hunan.关键词
钩端螺旋体/鼠/血清群/MLSTKey words
Leptospira/rodent/serogroup/MLST分类
医药卫生引用本文复制引用
邱海燕,肖明霞,张翠彩..2020-2022年湖南省鼠类钩端螺旋体病监测与菌株分型[J].中国人兽共患病学报,2024,40(3):203-207,5.基金项目
国家重点研发计划项目(No.2022YFC2305304)、中国疾病预防控制中心传染病预防控制所创新型医疗产品评价标准化项目(No.TS202311)和公共卫生应急反应机制的运行-传染病防控(No.102393220020020000029)联合资助(邱海燕和肖明霞有同等贡献) Supported by the National Key Research and Development Program of China(No.2022YFC2305304),the Innovative medical product evaluation standardization project of National Institute for Communicable Disease Control and Prevention,Chinese Cen-ter for Disease Control and Prevention(No.TS202311)and the Operation of Public Health Emergency Response Mechanism-Prevention and Control of Infectious Diseases(No.102393220020020000029).Qiu Hai-yan and Xiao Ming-xia contributed equal-ly to this article. （No.2022YFC2305304）
